利培酮(Risperidone) - 药物靶点：5-HT2A receptor x D2 receptor_在研适应症：躁郁症1型，易激惹，自闭症_专利_临床

概要

基本信息

简介利培酮（商品名为：RISPERDAL®）是一种非典型抗精神病药物。该药品由强生公司开发，于1993年12月29日获得美国食品药品监督管理局（FDA）批准。利培酮用于治疗精神分裂症，以及与双相I型障碍相关的急性躁狂或混合发作，可作为单药治疗或与锂或丙戊酸辅助治疗。此外，该药品还被批准用于治疗与自闭症谱系障碍相关的烦躁情绪。该药品通过抑制多巴胺2型（D2）和5-羟色胺2型（5HT2）受体结合起作用，这被认为是其治疗精神分裂症的疗效贡献之一。利培酮一般耐受性较好，但可能会引起体重增加、嗜睡和锥体外系症状等副作用。

药物类型

小分子化药

别名

Risperdal OD、Risperidone (JP17/USP/INN)、Risperidone for Depot Suspension

+ [40]

靶点

5-HT2A receptor x D2 receptor

作用机制

5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor拮抗剂(多巴胺D2受体拮抗剂)

治疗领域

其他疾病

在研适应症

躁郁症1型易激惹自闭症+ [3]

非在研适应症

急性精神分裂症阿尔茨海默症阿斯伯格综合症+ [25]

原研机构

Johnson & Johnson

在研机构

Laboratorios Farmaceúticos Rovi SA

山东绿叶制药有限公司

Dr. Reddy's Laboratories Ltd.

+ [7]

非在研机构

Janssen Pharmaceutica NVJanssen-Cilag International NVJanssen-Cilag Ltd.

+ [10]

最高研发阶段批准上市

首次获批日期

美国 (1993-12-29),

精神分裂症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C23H27FN4O2

InChIKeyRAPZEAPATHNIPO-UHFFFAOYSA-N

CAS号106266-06-2

关联

511

项与利培酮相关的临床试验

CTRI/2024/09/073270 / Not yet recruitingN/A

An open label, balanced, randomized, crossover, two-treatment, two-period, two-sequence, multiple dose, multi-center, steady state bioequivalence study of Risperidone Long acting Injection 25 mg/vial of Amneal EU, Limited and Rispolept® Consta® 25 mg Risperidone powder and solvent for injectable suspension prolonged release of Janssen Pharmaceutica NV Turnhoutseweg 30, B-2340, Beerse, Belgium, in subjects with schizophrenia - Nil

开始日期2024-09-13

申办/合作机构

Amneal EU Ltd.

IRCT20240527061909N1 / Recruiting临床3期IIT

Investigation of the efficacy of Risperidone in the treatment of developmental stuttering in Persian-speaking children aged 5 to 10 years

开始日期2024-08-22

申办/合作机构

Babol University of Medical Sciences

CTRI/2024/07/071680 / Not yet recruiting临床4期IIT

A comparative study of the safety of Risperidone with Olanzapine in patients of new-onset psychosis - NIL

开始日期2024-08-20

申办/合作机构

Dr. Rajendra Prasad Government Medical College

100 项与利培酮相关的临床结果

登录后查看更多信息

100 项与利培酮相关的转化医学

登录后查看更多信息

100 项与利培酮相关的专利（医药）

登录后查看更多信息

10,003

项与利培酮相关的文献（医药）

2024-12-01·IBRO Neuroscience Reports

The antipsychotic potential of Salix Mucronata on ketamine-induced rats

Article

作者: Mabandla, Musa V ; Ngubane, Ntombifuthi P ; De Gama, Brenda Z

Salix mucronata is one of the herbal plants offered by the traditional health practitioners in KwaZulu-Natal, South Africa for the treatment of schizophrenia. This study aimed to investigate the effects of repeated administration of ketamine on social interaction, novelty and motivation in adult, male Sprague Dawley rats. It also aimed to investigate the potential of risperidone and the herbal extract of S. mucronata to reverse impairments that are induced by ketamine. Experimental rats (n=45) received a dose of ketamine at 30 mg/kg via intraperitoneal injection for 5 consecutive days. They were then allocated into their respective treatment groups and given risperidone (APD) and the herbal extract of S. mucronata (TM) at doses of 6 mg/kg and 5 mg/kg, respectively, for 7 consecutive days. Social behaviour was tested using the 3-chambered sociability test, and anhedonia was tested using the sucrose preference test. Ketamine induction elicited social withdrawal and reduced social novelty which were later successfully reversed by risperidone and S. mucronata. The rats showed reduced preference to sucrose post-induction and post-treatment. Ketamine and mild stress caused by scruff restraint elicited reduced weight gain for the animals. No differences were noted on brain mass between controls and experimental groups and also between risperidone and S. mucronata groups. However, reduced brain volume was noted in experimental groups. Dopamine and acetylcholine concentration levels were high in groups which received risperidone and S. mucronata. These findings highlight that the antipsychotic potential of S. mucronata is similar to risperidone.

2024-12-01·Toxicology reports

Elucidating of the metabolic impact of risperidone on brain microvascular endothelial cells using untargeted metabolomics-based LC-MS

Article

作者: Ayutthaya, Watcharaporn Devakul Na ; Lohwacharin, Jenyuk ; Mo, Jiajun ; Pornchokchai, Krittaboon ; Hongthawonsiri, Patipol ; Wongpitoonmanachai, Siriphattarinya ; Pholkla, Petchlada ; Ngamratanapaiboon, Surachai ; Duchda, Phichanan ; Srikornvit, Napatarin ; Yambangyang, Pracha

Risperidone is useful for the treatment of schizophrenia symptoms; however, it also has side effects, and an overdose can be harmful. The metabolic effects of risperidone at high therapeutic doses and its metabolites have not been elucidated. Endogenous cellular metabolites may be comprehensively analyzed using untargeted metabolomics-based liquid chromatography-mass spectrometry (LC-MS), which can reveal changes in cell regulation and metabolic pathways. By identifying the metabolites and pathway changes using a nontargeted metabolomics-based LC-MS approach, we aimed to shed light on the potential toxicological effects of high-dose risperidone on brain microvascular endothelial cells (MVECs) associated with the human blood brain barrier. A total of 42 metabolites were selected as significant putative metabolites of the toxicological response of high-dose risperidone in MVECs. Six highly correlated pathways were identified, including those involving diacylglycerol, fatty acid, ceramide, glycerophospholipid, amino acid, and tricarboxylic acid metabolism. We demonstrated that methods focused on metabolomics are useful for identifying metabolites that may be used to clarify the mechanism of drug-induced toxicity.

2024-12-01·PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Adult and adolescent antipsychotic exposure increases delay discounting and diminishes behavioral flexibility in male C57BL/6 mice

Article

作者: Haste, D. Austin ; Newland, M Christopher ; Haste, D Austin ; Morrow, Carleigh ; Newland, M. Christopher ; Kendricks, Dalisa R. ; Kendricks, Dalisa R

Second-generation antipsychotics are frequently prescribed to adolescents, but the long-term consequences of their use remain understudied. These medications work via monoamine neurotransmitter systems, especially dopamine and serotonin, which undergo considerable development and pruning during adolescence. Dopamine and serotonin are linked to a wide host of behaviors, including impulsive choice and behavioral plasticity. In a murine model of adolescent antipsychotic use, male C57BL/6 mice were exposed to either 2.5 mg/kg/day risperidone or 5 mg/kg/day olanzapine via drinking water from postnatal days 22-60. To determine whether the adolescent period was uniquely sensitive to antipsychotic exposure, long-term effects on behavior were compared to an equivalently exposed group of adults where mice were exposed to 2.5 mg/kg risperidone from postnatal days 101-138. Motor activity and body weight in adolescent animals were assessed. Thirty days after exposure terminated animal's behavioral flexibility and impulsive choice were assessed using spatial discrimination reversal and delay discounting. Antipsychotic exposure produced a modest change in behavior flexibility during the second reversal. There was a robust and reproducible difference in impulsive choice: exposed animals devalued the delayed alternative reward substantially more than controls. This effect was observed both following adolescent and adult exposure, indicating that an irreversible change in impulsive choice occurs regardless of the age of exposure.

304

项与利培酮相关的新闻（医药）

2024-09-23

·米内网

【市场】湖南药企拿下4亿抗精神病药

精彩内容日前，国家药监局官网显示，湖南洞庭药业的利培酮口崩片以仿制4类报产获批，视同过评，是该产品第4家国产企业。米内网数据显示，利培酮口崩片在2023年中国三大终端六大市场（统计范围见文末）销售规模超过4亿元，是抗精神病化药TOP6产品。来源：米内网项目进度数据库利培酮口崩片是一种选择性的单胺能拮抗剂，具有改善精神分裂症症状的作用，可用于治疗精神分裂症、双相情感障碍的躁狂发作。 2023年中国三大终端六大市场抗精神病化药TOP10产品来源：米内网格局数据库利培酮口崩片在近年中国三大终端六大市场销售规模持续增长，2023年超过4亿元，同比增长8.18%，是抗精神病化药TOP6产品。米内网数据显示，利培酮口崩片有湖南洞庭药业、齐鲁制药等4家企业拥有生产批文，且均已过评，兰西哈三联制药、河北龙海药业、北京星昊医药均以仿制4类报产在审，获批后视同过评。今年以来，湖南洞庭药业已有利培酮口崩片和左乙拉西坦缓释片获批上市，米氮平片报产在审。米氮平片在2023年中国三大终端六大市场销售额超过7亿元，是抗抑郁化药TOP4产品。资料来源：国家药监局官网、米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准一致性评价

2024-09-23

·Business Wire

Medincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®

MONTPELLIER, France--( BUSINESS WIRE )-- New data presented by Teva at ECNP 2024 * demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris ® (RBP-7000) provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identified. Perseris manufacturer announced in July 2024 the discontinuation of its commercialization. Teva already presented in June 2024 data informing clinical strategies for switching patients to UZEDY from a once-monthly intramuscular injection of Invega Sustenna ® (paliperidone palmitate) ** . Richard Malamut, Chief Medical Officer of Medincell said: “We are delighted to see that our partner is fully committed to supporting healthcare providers in implementing effective switching strategies to UZEDY, which offers several key differentiating features compared to other risperidone or paliperidone palmitate formulations: no loading doses or oral supplementation at initiation, flexible dosing intervals of either one or two months, subcutaneous administration, ready-to-use prefilled syringe.” About additional results from the Advance study on the utilization of long-acting injectable antipsychotics, which were also reported by Teva at ECNP 2024, Richard Malamut said: “ It is encouraging to see that most of the factors raised by patients with Schizophrenia, their caregivers, and healthcare providers regarding use of a long-acting injectable antipsychotic can be effectively addressed with UZEDY.” ACCESS HERE THE COMPLETE PRESS RELEASE * 37 th Annual European College of Neuropsychopharmacology (ECNP) Congress - September 21-24, 2024, Milan, Italy. www.ecnp.eu ** Medincell’s press release, June 3 rd , 2024: https://www.medincell.com/wp-content/uploads/2024/06/PR_MDC_Elevate2024_EN_vf.pdf About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO ® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO ® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY ® (BEPO ® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. UZEDY ® and SteadyTeq™ are trademarks of Teva Pharmaceuticals www.medincell.com

上市批准生物类似药

2024-09-23

·Business Wire

Medincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®

MONTPELLIER, France--( BUSINESS WIRE )-- New data presented by Teva at ECNP 2024 * demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris ® (RBP-7000) provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identified. Perseris manufacturer announced in July 2024 the discontinuation of its commercialization. Teva already presented in June 2024 data informing clinical strategies for switching patients to UZEDY from a once-monthly intramuscular injection of Invega Sustenna ® (paliperidone palmitate) ** . Richard Malamut, Chief Medical Officer of Medincell said: “We are delighted to see that our partner is fully committed to supporting healthcare providers in implementing effective switching strategies to UZEDY, which offers several key differentiating features compared to other risperidone or paliperidone palmitate formulations: no loading doses or oral supplementation at initiation, flexible dosing intervals of either one or two months, subcutaneous administration, ready-to-use prefilled syringe.” About additional results from the Advance study on the utilization of long-acting injectable antipsychotics, which were also reported by Teva at ECNP 2024, Richard Malamut said: “ It is encouraging to see that most of the factors raised by patients with Schizophrenia, their caregivers, and healthcare providers regarding use of a long-acting injectable antipsychotic can be effectively addressed with UZEDY.” ACCESS HERE THE COMPLETE PRESS RELEASE * 37 th Annual European College of Neuropsychopharmacology (ECNP) Congress - September 21-24, 2024, Milan, Italy. www.ecnp.eu ** Medincell’s press release, June 3 rd , 2024: https://www.medincell.com/wp-content/uploads/2024/06/PR_MDC_Elevate2024_EN_vf.pdf About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO ® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO ® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY ® (BEPO ® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. UZEDY ® and SteadyTeq™ are trademarks of Teva Pharmaceuticals www.medincell.com

上市批准生物类似药

100 项与利培酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00426	利培酮	N05AX08	DB00734

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
自闭症	美国	Janssen Pharmaceuticals, Inc.	2006-10-06
易激惹	美国	Janssen Pharmaceuticals, Inc.	2006-10-06
躁郁症1型	美国	Janssen Pharmaceuticals, Inc.	2003-12-04
躁郁症	美国	Janssen Pharmaceuticals, Inc.	2002-03-03
精神分裂症	美国	Janssen Pharmaceuticals, Inc.	1993-12-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性精神分裂症	临床3期	美国	Indivior, Inc.	2014-04-01
自杀意念	临床3期	美国	Janssen Pharmaceuticals, Inc.	2004-06-01
创伤后应激障碍	临床3期	美国	Janssen Pharmaceuticals, Inc.	2004-04-01
广泛性焦虑障碍	临床3期	美国	Janssen Pharmaceuticals, Inc.	2004-02-01
恐慌	临床3期	美国	Janssen Pharmaceuticals, Inc.	2004-02-01
儿童行为障碍	临床3期	-	Janssen-Cilag Ltd.	2003-09-01
学习障碍	临床3期	-	Janssen-Cilag Ltd.	2003-09-01
难治性抑郁症	临床3期	-	Janssen LP	2002-10-01
难治性抑郁症	临床3期	-	Johnson & Johnson Pharmaceutical Research & Development LLC	2002-10-01
阿尔茨海默症	临床3期	-	Janssen Pharmaceuticals, Inc.	2002-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03323437 (CTgov)	临床4期	精神分裂症 \| 精神障碍	26	Risperidone (Patient)	淵鹹遞築鏇範製醖襯觸(糧簾淵築範繭壓鏇鏇顧) = 選遞願選夢齋積憲範簾窪鹹醖積觸淵淵築願觸 (選積醖廠壓積鹹膚獵廠, 蓋顧築鹽積窪淵鑰鹽願 ~ 製構窪製獵範糧製醖廠) 更多	-	2024-05-06
				risperidone (Control)	淵鹹遞築鏇範製醖襯觸(糧簾淵築範繭壓鏇鏇顧) = 鹹築願廠鏇鹹選鏇積鑰窪鹹醖積觸淵淵築願觸 (選積醖廠壓積鹹膚獵廠, 築醖糧構襯憲製鬱顧夢 ~ 蓋醖醖簾願淵餘獵構糧) 更多
NCT04418466 (PRNewswire) 人工标引	临床1/2期	精神分裂症	28	DLP-114	觸衊獵蓋蓋鹽壓壓築鏇(構糧廠簾壓艱夢獵艱築) = No serious adverse events (AEs) attributed to DLP-114 were reported, and DLP-114 was well tolerated for up to 12 months, including the initial placement and follow-up removal procedures 築遞觸壓遞遞衊淵夢壓 (夢憲壓壓願選製築遞壓 ) 更多	积极	2023-11-16
NCT03503318 (RISE, Literature) 人工标引	临床3期	精神分裂症	544	TV-46000 once monthly	襯糧獵築膚淵衊鹽鬱艱(襯鏇鑰淵餘簾遞鑰膚顧) = significantly prolonged by 5·0 times with TV-46000 once monthly (hazard ratio, 0·200 [95% CI 0·109–0·367]; p<0·0001) and by 2·7 times with TV-46000 once every 2 months (0·375 [0·227–0·618]; p<0·0001) versus placebo. 壓膚憲壓願鏇襯遞積鬱 (艱膚窪範鹽襯夢醖築憲 ) 更多	积极	2023-11-01
				TV-46000 once every 2 months
Literature 人工标引	N/A	急性精神分裂症	58	注射用利培酮微球（Ⅱ）	鏇淵製簾顧鏇積襯鏇壓(廠夢構鑰構衊鹹蓋艱範) = 2、4、 6 及 8 周末患者 PANSS 总分减分有效率分别为 37.9%（22/58）、70.7%（41/58）、89.7%（52/58）和 89.7%（52/58）醖齋鹽衊艱構簾襯鹽醖 (衊製顧鬱範艱願窪夢繭 ) 更多	积极	2023-07-07
NCT03503318 (FDA) 人工标引	临床3期	精神分裂症	543	UZEDY	獵顧遞築簾襯蓋蓋積鬱(鏇構顧夢鏇廠顧夢衊艱) = The most common adverse reactions in clinical trials of oral risperidone (>5% and twice placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain. 鑰構衊繭鑰醖鬱衊選顧 (膚顧憲窪鑰窪築顧遞獵 ) 更多	积极	2023-04-28
				Placebo
ASN2022	N/A	精神分裂症	-	Risperidone	鬱衊願獵憲獵網廠憲衊(糧襯繭壓鬱鬱選糧網齋) = 蓋獵選齋廠鬱簾憲醖鏇鹹顧淵構繭鑰廠製蓋襯 (積窪膚範襯憲齋遞製襯 )	积极	2022-11-05
				Control (no risperidone use)	鬱衊願獵憲獵網廠憲衊(糧襯繭壓鬱鬱選糧網齋) = 廠顧遞繭構鹽願鑰壓鏇鹹顧淵構繭鑰廠製蓋襯 (積窪膚範襯憲齋遞製襯 )
NCT03893825 (SHINE, CTgov)	临床3期	精神分裂症	336	TV-46000 (TV-46000 q1m)	網鹽製願鏇鏇獵鹹簾憲(選製遞範鬱鑰觸願鹽築) = 憲繭淵夢積壓蓋觸鑰艱網願構網膚壓構糧網壓 (膚鑰艱顧鑰鏇窪淵簾範, 壓淵積網鑰膚範構夢壓 ~ 鹽製繭壓繭膚繭積艱壓) 更多	-	2022-10-04
				Placebo+TV-46000 (TV-46000 q2m)	網鹽製願鏇鏇獵鹹簾憲(選製遞範鬱鑰觸願鹽築) = 鹽齋鬱夢獵糧構觸餘簾網願構網膚壓構糧網壓 (膚鑰艱顧鑰鏇窪淵簾範, 顧願顧夢簾願遞顧膚構 ~ 醖選範願餘簾廠膚簾衊) 更多
NCT03503318 (RISE, CTgov)	临床3期	精神分裂症	544	Placebo (Placebo)	憲觸鑰憲鑰廠淵鏇製繭(鏇餘鑰糧積鬱鬱網鹽獵) = 襯鏇襯衊憲鹽繭憲願壓願蓋蓋觸餘襯糧蓋窪觸 (淵製餘積鏇選糧鏇蓋製, 齋醖鑰顧範鏇衊夢構觸 ~ 蓋艱顧壓膚構觸夢獵獵) 更多	-	2021-12-09
				TV-46000 (TV-46000 q1m)	憲觸鑰憲鑰廠淵鏇製繭(鏇餘鑰糧積鬱鬱網鹽獵) = 鑰鬱簾繭積選壓夢積膚願蓋蓋觸餘襯糧蓋窪觸 (淵製餘積鏇選糧鏇蓋製, 襯構繭構鏇衊範構繭糧 ~ 襯網網鹽築顧餘簾齋鹽) 更多
NCT03978832 (CTgov)	临床4期	精神分裂症	69	Risperidone	壓鑰鹽衊淵鑰範積膚淵(選膚廠窪襯淵艱糧膚醖) = 鑰壓壓構簾齋選願膚鑰鹽膚壓繭艱積夢壓顧繭 (選選齋鬱獵夢餘願襯夢, 襯積築鑰齋積遞齋網製 ~ 願製鏇簾膚鹹鑰遞鬱構) 更多	-	2021-07-07
NCT00221403 (CTgov)	临床3期	躁郁症	46	Valproate Oral Solution (Valproate (VPA))	簾憲鬱簾顧糧廠壓艱鏇(觸網顧鏇壓構窪選鏇鏇) = 蓋鹹蓋衊蓋積蓋簾鹹壓構鬱製夢糧網鹹鑰憲鹹 (壓鹽壓遞顧鏇選憲鏇製, 築願窪鑰艱艱糧膚鬱廠 ~ 壓觸選鹽淵範鹽構壓壓)	-	2020-10-20
				Risperidone oral solution (Risperidone)	簾憲鬱簾顧糧廠壓艱鏇(觸網顧鏇壓構窪選鏇鏇) = 簾觸淵繭積膚製觸遞積構鬱製夢糧網鹹鑰憲鹹 (壓鹽壓遞顧鏇選憲鏇製, 製齋簾蓋憲範獵構製衊 ~ 遞衊憲遞鑰觸製醖艱鏇) 更多